BERG Presents New Research Using AI and Multi-Omics Toward Identification of Multiple Clinical Outcome Biomarkers for Systemic Lupus Erythematosus at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting

BOSTON, Oct. 25, 2018 /PRNewswire/ -- BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, yesterday presented findings that reveal potential biomarkers of disease activity in Systemic Lupus Erythematosus (SLE) in an oral presentation at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago.

"The data being presented reinforces the power and potential of our Interrogative Biology^® platform and AI-driven research to understand the pathology of disease and identify new targets for further exploration and validation," said Niven R. Narain, Ph.D., BERG Co-founder, President and Chief Executive Officer. "Biomarker-driven treatment approaches are critical as we move toward an era of precision medicine that will enable us to identify patients with lupus and other autoimmune rheumatic diseases most likely to achieve an improved treatment response, risk determination and benefit."

The presentation, "Systemic Lupus Erythematosus Biomarkers Identified Using Multi-Omic and Artificial Intelligence Analysis through Interrogative Biology" detailed the utilization of BERG's proprietary Interrogative Biology platform to conduct biological, multi-omic analysis (e.g., metabolomics, lipidomics and proteomics) in combination with artificial intelligence (AI) to discover serum and urine-based candidate biomarkers of lupus.

Presentation and Data Summary:

• Title: Systemic Lupus Erythematosus Biomarkers Identified Using Multi-Omic and Artificial Intelligence Analysis through Interrogative Biology^®
• Presenter: Eric Grund, Ph.D., Lead Investigator and Senior Director of Program Management, Discovery Sciences, BERG
• Date: October 24, 2018, 9:00 a.m. – 10:30 a.m. CDT
• Abstract Number: 2932

"Informative biomarkers for use in developing diagnostics and treatments for lupus is a large clinical unmet need, particularly due to the wide differential in patient progression and outcomes experienced by patients," said Eric Grund, Ph.D., Lead Investigator and Senior Director of Program Management, Discovery Sciences at BERG. "By utilizing BERG's unique platforms and data-driven approach to map and deconstruct disease, we have identified a number of informative biomarkers of interest for further investigation which may impact patient outcomes and quality of life."

About BERG
BERG LLC is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology^®, to map disease and revolutionize treatments across oncology, neurology and rare diseases. By taking a Back to Biology^™ approach, BERG is able to identify critical biomarkers that can accelerate the discovery and development of treatments aimed at the most promising therapeutic targets and pathways. BERG has leveraged both Interrogative Biology and traditional R&D methods to develop a robust pipeline of first-in-class product candidates and diagnostics that advance bold innovations that have the potential to improve patient lives. To learn more about how we're enabling bold innovation, visit berghealth.com.

Media Contact:
Chris Dougherty
Ogilvy
917-515-9876
[email protected]

BERG Investor Contact: 
Molly Cameron 
BERG 
617-588-1000 
[email protected]

SOURCE BERG